Studies Investigating Predictive Ability of End-of-Treatment PET Imaging in NHL
| Results | ||||
| Study | Patient population | Treatment regimen | PET+ | PET− |
| Bishu, 2007 (71) | 31 FL patients | Nonuniform | Median PFS: 5.8 mo | Median PFS: 29.5 mo |
| Zinzani, 2007 (72) | 45 FL patients | 6 cycles (R-FM, R-CHOP) | 2-y PFS: 20% | 2-y PFS: 90% |
| Itti, 2009 (73) | 80 DLBCL patients (10 limited, 70 advanced) | 4 cycles (CHOP, R-CHOP, ACVBP/ACE, R-ACVBP) | 2-y EFS: 25% | 2-y EFS: 82% |
| Le Dortz, 2010 (74) | 45 FL patients | 6 cycles (R-CHOP) | Median PFS: 17.2 mo | Median PFS: 48.0 mo |
| Trotman, 2011 (9) | 122 FL patients (14 limited, 108 advanced) | 6 cycles (R-CHOP), 8 cycles (R-CVP) | 42-mo PFS: 32.9% | 42-mo PFS: 70.7% |
| Dupuis, 2012 (33) | 121 FL patients | 6 cycles (R-CHOP) | 2-y PFS: 51% | 2-y PFS: 87% |
| Pregno, 2012 (29) | 88 DLBCL patients (29 limited, 59 advanced) | 2–4 cycles (R-CHOP) | 2-y PFS: 64% | 2-y PFS: 83% |
| Mato, 2012 (75) | 148 mantle cell lymphoma patients | R-HyperCVAD, rituximab-cytarabine/methotrexate | Median PFS: 11.1 mo; median OS: 56.9 mo | Median PFS: not reached; median OS: not reached |
| Zinzani, 2013 (76) | 142 intermediate- to high-risk FL patients | 6 cycles (R-FM) | 5-y PFS: 42% | 5-y PFS: 76% |
| Khong, 2014 (31) | 24 natural killer/T-cell lymphoma patients | 6 cycles (SMILE) | 2-y PFS: 0%; 2-y OS: 0% | 2-y PFS: 68%; 2-y OS: 91% |
| Lu, 2014 (39) | 47 indolent-FL patients | 6 cycles (R-CHOP) | Median OS: 45.0 mo | Median OS: 95.2 mo |
| Luminari, 2014 (77) | 202 FL patients | 8 cycles (R-CVP), 6 cycles (R-CHOP, R-FM) | 3-y PFS: 35% | 3-y PFS: 66% |
| Martelli, 2014 (78) | 115 PMLBCL patients | Rituximab, anthracycline | 5-y PFS: 68%; 5-y OS: 83% | 5-y PFS: 99%; 5-y OS: 100% |
| Tychyj-Pinel, 2014 (79) | 119 FL patients | 6 cycles (R-CHOP), 8 cycles (R-CVP) | 42-mo PFS: 25.0% | 42-mo PFS: 61.4% |
| Priel, 2015 (40) | 33 Burkitt lymphoma patients | 6 cycles (GMALL B-ALL/NHL 2002 protocol) | 3-y OS: 30% | 3-y OS: 90% |
FL = follicular lymphoma; R-FM = rituximab, fludarabine, and mitoxantrone; PMLBCL = primary mediastinal large B-cell lymphoma; ACVBP/ACE = adriamycin, cyclophosphamide, vindesine, bleomycin, prednisone/adriamycin, cyclophosphamide, etoposide; R-ACVBP = rituximab, adriamycin, cyclophosphamide, vindesine, bleomycin, and prednisone; EFS = event-free survival; R-CVP = rituximab, cyclophosphamide, vincristine, prednisone; R-HyperCVAD = rituximab, cyclophosphamide, doxorubicin, vincristine, dexamethasone alternating with cytarabine, and methotrexate; OS = overall survival; SMILE = dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide; GMAL B-ALL/NHL 2002 protocol = rituximab, high-dose methotrexate, high-dose cytosine arabinoside, cyclophosphamide, etoposide, iphosphamide, corticosteroid, triple-intrathecal therapy.